Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Page Not Found
Cart summary

You have no items in your shopping cart.

MSDC-0160

SKU: orb1226229

Description

A new generation insulin sensitizer and mitochondrial target of thiazolidinediones (mTOT) modulator that has low affinity for binding and activation of PPARγ (EC50=23.7 uM) and shows insulin-sensitizing effects in mouse models of diabetes; increases AMPK activity and reduces mTOR activity, maintains β-cell phenotype in human islets.Diabetes Phase 2 Clinical(In Vitro):MSDC 0160 (Mitoglitazone; 1-50 μM; for 24 hours) significantly decreases phosphorylation of mTOR at 20 and 50 μM.MSDC 0160 acts as insulin sensitizers without activating PPARγ.MSDC 0160 (10 μM; pretreatment 1 hour) prevents the MPP+ (10 μM)-induced loss of both tyrosine hydroxylase (TH)-immunoreactive differentiated Lund human mesencephalic (LUHMES) cells.MSDC 0160 (10 or 100 μM) prevents the loss of GFP-fluorescent dopaminergic neurons induced by MPP+ (0.75 mM) in nematodes.MSDC 0160 (10-20 μM) in conbination with IGF-1 prevents the loss of insulin content and maintains insulin secretion.MSDC 0160 (1-50 μM) treatment maintains human β-cell phenotype.(In Vivo):MSDC 0160 (Mitoglitazone; 30 mg/kg; oral gavage; daily; for 7 days) improves locomotor behavior, increases survival of nigral dopaminergic neurons, boosts striatal dopamine levels, and reduces neuroinflammation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.

Images & Validation

Key Properties

CAS Number146062-49-9
MW370.4222
Purity>98% (HPLC)
FormulaC19H18N2O4S
SMILESO=C(N1)SC(CC2=CC=C(OCC(C3=NC=C(CC)C=C3)=O)C=C2)C1=O
TargetInsulin Receptor
SolubilityDMSO: ≥ 30 mg/mL

Bioactivity

In Vivo
Animal model: Ten-to 12-week-old male C57BL/6J mice weighing 24 to 28 g. Dosage: 30 mg/kg. Administration: Oral gavage; daily; for 7 days. Result: Improved locomotor behavior, increased survival of nigral dopaminergic neurons, boosted striatal dopamine levels, and reduced neuroinflammation.
In Vitro
Western blot analysis. Cell line: Human islets. Concentration: 1, 10, 20, 50 μM. Incubation time: For 24 hours. Result: Significantly decreased Phosphorylation of mTOR at 20 and 50 μM.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

PNU-91325 | Mitoglitazone

Similar Products

  • MSDC 0160 [orb1305270]

    98.11% (May vary between batches)

    146062-49-9

    370.42

    C19H18N2O4S

    2 mg, 10 mg, 50 mg, 100 mg, 1 ml x 10 mM (in DMSO), 1 mg, 5 mg, 25 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

MSDC-0160 (orb1226229)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

200 mg
500 mg
2 mg
$ 90.00
5 mg
$ 120.00
10 mg
$ 160.00
25 mg
$ 230.00
50 mg
$ 300.00
100 mg
$ 500.00